Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Mallinckrodt
Baxter
Colorcon
Dow

Last Updated: March 26, 2023

Investigational Drug Information for L-Alanine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug L-Alanine?

L-Alanine is an investigational drug.

There have been 11 clinical trials for L-Alanine. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Syndrome, Coronary Disease, and Coronary Artery Disease. The leading clinical trial sponsors are National Cancer Institute (NCI), Slocum Center for Orthopedics and Sports Medicine, and Nanjing Medical University.

There are one hundred and forty US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for L-Alanine
TitleSponsorPhase
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin α1) VBeijing Anzhen HospitalN/A
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin α1) VNanjing Medical UniversityN/A
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19National Cancer Institute (NCI)Phase 2

See all L-Alanine clinical trials

Clinical Trial Summary for L-Alanine

Top disease conditions for L-Alanine
Top clinical trial sponsors for L-Alanine

See all L-Alanine clinical trials

US Patents for L-Alanine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
L-Alanine See Plans and Pricing Synthetic polymeric drugs Ceskoslovenska Akademie Ved (Praha, CS) Carlton Medical Products Limited (London, GB2) See Plans and Pricing
L-Alanine See Plans and Pricing Substituted amino acid compounds Adir et Compagnie (Courbevoie, FR) See Plans and Pricing
L-Alanine See Plans and Pricing Solid phase peptide synthesis using a polyacrylic support in aqueous solution Societe d'Expansion Scientifque Expansia (FR) See Plans and Pricing
L-Alanine See Plans and Pricing Cyclic anticoagulant peptides Merrell Dow Pharmaceuticals Inc. (Cincinnati, OH) See Plans and Pricing
L-Alanine See Plans and Pricing Amino nitrile intermediate for the preparation of alanine diacetic acid The Dow Chemical Company (Midland, MI) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for L-Alanine

Drugname Country Document Number Estimated Expiration Related US Patent
L-Alanine Austria AT60991 2005-01-04 See Plans and Pricing
L-Alanine Australia AU5183386 2005-01-04 See Plans and Pricing
L-Alanine Australia AU589587 2005-01-04 See Plans and Pricing
L-Alanine Canada CA1305053 2005-01-04 See Plans and Pricing
L-Alanine Germany DE3581921 2005-01-04 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Mallinckrodt
Baxter
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.